International Journal of Endocrinology / 2014 / Article / Tab 1

Clinical Study

Response to Initial Therapy of Differentiated Thyroid Cancer Predicts the Long-Term Outcome Better than Classical Risk Stratification Systems

Table 1

Clinical outcomes at the end of follow-up period.

(1) No evidence of disease after initial therapy 
(i) Undetectable suppressed and stimulated TG 
(ii) No evidence of structural disease by neck US and diagnostic 131I whole body scan 
(iii) No need for additional therapy

(2) No evidence of disease after additional therapy 
(i) Undetectable suppressed and stimulated TG 
(ii) No evidence of structural disease by neck US, diagnostic 131I whole body scan, and other cross-sectional imaging  
if performed (CT scan, MRI, FDG-PET scan, bone scintigraphy)  
(iii) Need for additional therapy (surgery, second dose of ablative 131I, and chemotherapy)

(3) Persistent biochemical disease 
(i) Suppressed TG ≥ 1 ng/mL or stimulated TG ≥ 2 ng/mL 
(ii) No evidence of structural disease by neck US, diagnostic 131I whole body scan, and other cross-sectional  
imaging if performed (CT scan, MRI, FDG-PET scan, bone scintigraphy)

(4) Persistent structural disease 
Any evidence of disease on neck US, diagnostic 131I whole body scan, and other cross-sectional imaging (CT scan,  
MRI, FDG-PET scan, bone scintigraphy) or biopsy proven disease

(5) Disease specific mortality

CT: computerized tomography; MRI: magnetic resonance imaging; FDG-PET: fluorodeoxyglucose positron emission tomography.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.